PMID- 36249780
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221019
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - The efficacy and adverse events of delafloxacin in the treatment of acute 
      bacterial infections: A systematic review and meta-analysis of randomized 
      controlled trials.
PG  - 975578
LID - 10.3389/fphar.2022.975578 [doi]
LID - 975578
AB  - Background: This study aims to assess the clinical efficacy and adverse events of 
      delafloxacin for the treatment of acute bacterial infections in adult patients 
      through meta-analysis. Methods: The PubMed, Embase, Cochrane library, Web of 
      Science, and Clinical trails databases were searched up to 26 March 2022. Only 
      randomized controlled trials (RCTs) that evaluated delafloxacin and comparator 
      antibiotics for treating acute bacterial infections in adult patients were 
      included. The clinical cure rate and microbiological eradication rate at the 
      posttreatment evaluation, while the secondary outcomes included the risk of 
      adverse events (AEs). Results: In total, six randomized controlled trials (RCTs) 
      involving 3,019 patients with acute bacterial infection were included. There were 
      no significant differences in the clinical cure rate between delafloxacin and 
      comparators (OR = 1.06%, 95% CI = 0.89-1.26, I(2) = 0%). Overall, the results 
      showed that delafloxacin had a microbiological eradication rate (documented and 
      presumed) similar to the comparators (OR = 1.33%, 95% CI = 0.94-1.88, I(2) = 0%) 
      in the pooled analysis of the six studies. Any treatment-emergent adverse events 
      (TEAEs) did not show significant differences between delafloxacin and the 
      comparators (OR = 0.93%, 95% CI = 0.80-1.08, I(2) = 75%). Serious adverse events 
      (SAEs) did not differ between the delafloxacin and comparators (OR = 0.94%, 95% 
      CI = 0.67-1.32, I(2) = 0%). The results of gastrointestinal disorders were (OR = 
      1.26%, 95% CI = 1.01-1.56, I(2) = 89%), and nausea, vomiting, and diarrhea were 
      (OR = 0.77%, 95% CI = 0.45-1.34, I(2) = 79%), (OR = 1.00%, 95% CI = 0.74-1.36, 
      I(2) = 72%), and (OR = 2.10%, 95% CI = 1.70-2.96, I(2) = 0%), respectively. The 
      results showed that there was no significant difference in the incidence of 
      nausea and vomiting between delafloxacin and the comparator, but the incidence of 
      diarrhea was higher. The analysis of neurological disorders indicated that the 
      incidence of nervous system disorders was lower in the delafloxacin group (OR = 
      0.71%, 95% CI = 0.50-1.01, I(2) = 52%). Conclusion: The clinical efficacy, 
      microbiological eradication rate and the incidence of AEs of delafloxacin in the 
      treatment of acute bacterial infections were similar to those of the comparators, 
      as an alternative therapeutic agent.
CI  - Copyright (c) 2022 He, Lin, Yu, Qiu and Zheng.
FAU - He, Rong
AU  - He R
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital of Chengdu Medical College, Chengdu, China.
FAU - Lin, Fei
AU  - Lin F
AD  - Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, 
      Chengdu, China.
AD  - Sichuan Province College Key Laboratory of Structure-Specific Small Molecule 
      Drugs, Chengdu Medical College, Chengdu, China.
FAU - Yu, Bin
AU  - Yu B
AD  - Department of Pharmacy, Mianyang Central Hospital, Mianyang, China.
FAU - Qiu, Jingyue
AU  - Qiu J
AD  - Department of Pharmacy, PLA Strategic Support Force Medical Center, Beijing, 
      China.
FAU - Zheng, Lingli
AU  - Zheng L
AD  - Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, 
      Chengdu, China.
LA  - eng
PT  - Systematic Review
DEP - 20220928
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9554268
OTO - NOTNLM
OT  - S. aureu
OT  - acute bacterial infections
OT  - delafloxacin
OT  - efficacy
OT  - meta analysis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/18 06:00
MHDA- 2022/10/18 06:01
PMCR- 2022/09/28
CRDT- 2022/10/17 05:28
PHST- 2022/06/22 00:00 [received]
PHST- 2022/08/31 00:00 [accepted]
PHST- 2022/10/17 05:28 [entrez]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2022/10/18 06:01 [medline]
PHST- 2022/09/28 00:00 [pmc-release]
AID - 975578 [pii]
AID - 10.3389/fphar.2022.975578 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Sep 28;13:975578. doi: 10.3389/fphar.2022.975578. 
      eCollection 2022.